Supported telemonitoring improved HbA1c and blood pressure in type 2 diabetes
Punto clave:
In adults with poorly controlled type 2 diabetes in UK family practice, supported telemonitoring lowered HbA1c and ambulatory blood pressure more than usual care over 9 months, without changing weight.
Estudio de un vistazo
Qué se estudió
Whether supported telemonitoring improves diabetes and blood pressure control in primary care
Tipo de estudio
Randomized Controlled Trials (RCTs)
duration
Medium-Term (3–12 mo)
Intervención
Telemonitoring
Resultados
HbA1c, Systolic blood pressure, Diastolic blood pressure, Body weight
Financiamiento
No financiado por la industria
mainEffects
HbA1c ↓ by 0.51% versus usual care
Systolic blood pressure ↓ by 3.06 mmHg
Diastolic blood pressure ↓ by 2.17 mmHg
Body weight ↔ with no clear between-group difference
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Telemonitoring (Devices & Technology) |  Body weight (Weight & Anthropometrics) | Uncertain | Limited |
Telemonitoring (Devices & Technology) |  Diastolic blood pressure (Metabolic Health) | Decrease | Limited |
Telemonitoring (Devices & Technology) |  HbA1c (Glycemic Control) | Decrease | Strong |
Telemonitoring (Devices & Technology) | Systolic blood pressure (Metabolic Health) | Decrease | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Adjusted mean HbA1c was 5.60 mmol/mol lower in the telemonitoring group at 9 months.
- Ambulatory systolic and diastolic blood pressure were both lower with telemonitoring than with usual care.
- Weight, prescribing patterns, and most health service use measures were not clearly different between groups.
Who this applies to
These findings apply most directly to adults with type 2 diabetes in primary care who have poor glycemic control, can use home monitoring equipment, and have access to remote clinician follow-up. The results are especially relevant to UK-style family practice settings, but may also inform similar telehealth programs elsewhere.
Keep in Mind
This was a structured telemonitoring program, not simple unsupported self-monitoring. Participants transmitted readings, and clinicians reviewed results regularly and contacted patients when needed. The benefits may depend on that support model, patient engagement, and the local health system’s ability to respond to incoming data. It is also not yet clear whether the improvement lasts after monitoring stops.
Between the Lines
- Participants and clinicians could not be fully blinded to group assignment.
- Only a minority of invited eligible patients joined the trial, so participants may not represent all patients with poorly controlled diabetes.
- The study did not show how long the benefit lasts after the 9-month intervention ends.
- The exact mechanism of benefit was unclear because medication changes and self-management behavior may both have contributed.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Referencia de la Revista
Wild SH, Hanley J, Lewis SC, et al. Supported Telemonitoring and Glycemic Control in People with Type 2 Diabetes: The Telescot Diabetes Pragmatic Multicenter Randomized Controlled Trial. PLoS Med. 2016;13(7):e1002098. doi:10.1371/journal.pmed.1002098
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
Supporting Evidence
Supporting evidence and related resources.
A Guide for People with Type 2 Diabetes | American Diabetes Association
Diabetes in America: Prevalence, Statistics, and Economic Impact
Diabetes Medication | ADA
Managing Diabetes
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Impact of 12-Month mHealth Home Telemonitoring on Clinical Outcomes in Older Individuals With Hypertension and Type 2 Diabetes: Multicenter Randomized Controlled Trial.
13 total sources in this category
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.